Search
  • mmahomed2

Phase I SBIR grant from the National Cancer Institute

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provide sustained immune cell activation after intratumoral injection. Specifically, we will generate a therapeutic product that can be used to generate a system-wide immune response against metastatic melanomas cells after administration to only a subset of surface-accessible lesions.


32 views

Recent Posts

See All

Series A financing

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

© Valitor, Inc 2020

  • LinkedIn - White Circle